# A Pilot Study to Evaluate the Systemic Effect of Oral Supplementation With AM3 in Patients With Metabolic Syndrome.

> **NCT06158152** · NA · RECRUITING · sponsor: **Industrial Farmacéutica Cantabria, S.A.** · enrollment: 48 (estimated)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** AM3 + Probiotic
- **DIETARY_SUPPLEMENT:** Placebo
- **DIETARY_SUPPLEMENT:** AM3

## Key facts

- **NCT ID:** NCT06158152
- **Lead sponsor:** Industrial Farmacéutica Cantabria, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-20
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158152, "A Pilot Study to Evaluate the Systemic Effect of Oral Supplementation With AM3 in Patients With Metabolic Syndrome.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06158152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*